294 related articles for article (PubMed ID: 1795007)
1. Dosing and side-effects of ifosfamide plus mesna.
Brade WP; Herdrich K; Kachel-Fischer U; Araujo CE
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S164-86. PubMed ID: 1795007
[TBL] [Abstract][Full Text] [Related]
2. Ambulatory high-dose 5-day continuous-infusion ifosfamide combination chemotherapy in advanced solid tumors: a feasibility study.
Loeffler TM; Weber FW; Hausamen TU
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S125-8. PubMed ID: 1795000
[TBL] [Abstract][Full Text] [Related]
3. Phase I trial of a 24-h continuous infusion of ifosfamide/mesna in acute lymphoblastic leukemia.
Otero JC; Solidoro A; Casanova L; Vallejos C; Rodriguez W
J Exp Ther Oncol; 1996 Mar; 1(2):84-7. PubMed ID: 9414391
[TBL] [Abstract][Full Text] [Related]
4. Dose finding of ifosfamide administered with a chronic two-week continuous infusion.
Cartei G; Clocchiatti L; Sacco C; Pella N; Bearz A; Mantero J; Pastorelli D; Salmaso F; Zustovich F
Oncology; 2003; 65 Suppl 2():31-6. PubMed ID: 14586144
[TBL] [Abstract][Full Text] [Related]
5. Toxicity and response to high-dose ifosfamide + mesna as salvage therapy for advanced breast cancer.
Steger GG; Dittrich C; Schlappack O; Mader R; Herold C; Brade WP; Keller A; Moser K
J Cancer Res Clin Oncol; 1988; 114(6):602-4. PubMed ID: 3144554
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide continuous infusion without mesna. A phase I trial of a 14-day cycle.
Lokich I; Anderson N; Bern M; Moore C
Cancer; 1991 Feb; 67(4):883-5. PubMed ID: 1899352
[TBL] [Abstract][Full Text] [Related]
7. A retrospective study of treatment and prophylaxis of ifosfamide-induced hemorrhagic cystitis in pediatric and adolescent and young adult (AYA) patients with solid tumors.
Saito Y; Kumamoto T; Makino Y; Tamai I; Ogawa C; Terakado H
Jpn J Clin Oncol; 2016 Sep; 46(9):856-61. PubMed ID: 27380806
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
9. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
[TBL] [Abstract][Full Text] [Related]
10. Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G; Ghiani M; Lai P; Maccio A; Dessi D; Succu G; Massa D; Curreli L; Mulas C; Esu S; Proto E; Cadeddu G; Tore G
Oncol Rep; 1998; 5(6):1499-505. PubMed ID: 9769395
[TBL] [Abstract][Full Text] [Related]
11. Experience of the Belgian Society of Medical Oncology with single-administration 5 g/m2 ifosfamide with mesna as second- or third-line therapy in advanced breast cancer.
Paridaens R; Focan C; Michel J; Piccart M; Salamon E; Beauduin M; Closon MT; Tueni E; Vindevoghel A; Majois F
Cancer Chemother Pharmacol; 1990; 26 Suppl():S63-5. PubMed ID: 2112055
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of dose-intense ifosfamide plus epirubicin with hematopoietic growth factors for the treatment of patients with advanced soft tissue sarcomas; a novel sequential schedule.
Serrone L; Zeuli M; Gamucci T; Nardi M; Cognetti F
Cancer Chemother Pharmacol; 2001 Mar; 47(3):206-10. PubMed ID: 11320663
[TBL] [Abstract][Full Text] [Related]
13. Urinary excretion of ifosfamide, 4-hydroxyifosfamide, 3- and 2-dechloroethylifosfamide, mesna, and dimesna in patients on fractionated intravenous ifosfamide and concomitant mesna therapy.
Kurowski V; Wagner T
Cancer Chemother Pharmacol; 1997; 39(5):431-9. PubMed ID: 9054957
[TBL] [Abstract][Full Text] [Related]
14. Oral ifosfamide/mesna versus intravenous ifosfamide/mesna in non-small-cell lung cancer: a randomized phase II trial of the EORTC lung cancer cooperative group.
Manegold C; Drings P; Pawinski A; Lentz MA; van Glabbeke M; van Zandwijk N; Bachmann P; Schnaars Y; Skacel Z; Zatloukal P; Dolensky J; Jackevicius A; Petruzelka L; Giaccone G
Ann Oncol; 1996 Aug; 7(6):637-9. PubMed ID: 8879380
[TBL] [Abstract][Full Text] [Related]
15. Continuous 5-day infusion of ifosfamide with mesna in inoperable pancreatic cancer patients: a phase II study.
Cerny T; Martinelli G; Goldhirsch A; Terrier F; Joss R; Fey MF; Brunner KW; Küpfer A
J Cancer Res Clin Oncol; 1991; 117 Suppl 4():S135-8. PubMed ID: 1795002
[TBL] [Abstract][Full Text] [Related]
16. Tubular nephrotoxicity during long-term ifosfamide and mesna therapy.
Goren MP; Pratt CB; Viar MJ
Cancer Chemother Pharmacol; 1989; 25(1):70-2. PubMed ID: 2574077
[TBL] [Abstract][Full Text] [Related]
17. High-dose ifosfamide with mesna uroprotection in Ewing's sarcoma.
Jürgens H; Exner U; Kühl J; Ritter J; Treuner J; Weinel P; Winkler K; Göbel U
Cancer Chemother Pharmacol; 1989; 24 Suppl 1():S40-4. PubMed ID: 2503258
[TBL] [Abstract][Full Text] [Related]
18. Experience with 24-h infusions of ifosfamide/mesna in small cell lung cancer.
Cantwell BM; Harris AL; Bozzino JM
Cancer Chemother Pharmacol; 1986; 18 Suppl 2():S29. PubMed ID: 3028660
[TBL] [Abstract][Full Text] [Related]
19. A phase I study of prolonged ambulatory infusion of Ifosfamide with oral mesna.
Olver I; Keefe D; Myers M; Caruso D
Chemotherapy; 2005 May; 51(2-3):142-6. PubMed ID: 15886474
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide and mesna at high doses for the treatment of cancer of the cervix: a GETLAC study.
Cervellino JC; Araujo CE; Pirisi C; Sanchez O; Brosto M; Rossi R
Cancer Chemother Pharmacol; 1990; 26 Suppl():S1-3. PubMed ID: 2112052
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
